Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share:
Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In addition, NASH is expected to become the leading indicator for liver transplants in men.
Can-Fite BioPharma Ltd. (NYSE: CANF), an Israel-based biotechnology company, is advancing a pipeline of proprietary small-molecule drugs that address inflammatory, cancer and liver diseases and has received clearance from the Israeli Ministry of Health to begin a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. We are very pleased to receive the Israeli Ministry of Health s approval to proceed with our Phase IIb NASH study. We believe that Namodenoson could offer a safe and effective treatment for NASH, Can-Fite CEO Dr. Pnina Fishman said. Our overall goal is to reduce the need for liver transplants and improve the quality of life and longevity of patients.
by Mark Gilman
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule .
Can-Fite BioPharma Interview to Air on Bloomberg Television U S on the RedChip Money Report® streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.